1. Home
  2. LAB vs ADCT Comparison

LAB vs ADCT Comparison

Compare LAB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standard BioTools Inc.

LAB

Standard BioTools Inc.

HOLD

Current Price

$0.80

Market Cap

402.1M

Sector

Industrials

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$0.95

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAB
ADCT
Founded
1999
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
402.1M
431.2M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
LAB
ADCT
Price
$0.80
$0.95
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$1.35
$7.75
AVG Volume (30 Days)
3.0M
2.2M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
61.54
30.86
EPS
0.33
N/A
Revenue
$101,937,000.00
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.63
$66.49
P/E Ratio
$2.43
N/A
Revenue Growth
N/A
14.85
52 Week Low
$0.80
$0.78
52 Week High
$1.72
$4.98

Technical Indicators

Market Signals
Indicator
LAB
ADCT
Relative Strength Index (RSI) 34.65 11.51
Support Level N/A N/A
Resistance Level $1.02 $4.77
Average True Range (ATR) 0.10 0.19
MACD -0.01 -0.26
Stochastic Oscillator 2.43 5.36

Price Performance

Historical Comparison
LAB
ADCT

About LAB Standard BioTools Inc.

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: